HER2-targeted monoclonal antibody that blocks ERBB2 signaling and mediates ADCC.
Humanized IgG1 monoclonal antibody that binds the extracellular domain of HER2 (ERBB2), blocks receptor signaling and dimerization, and triggers antibody-dependent cellular cytotoxicity via Fcγ receptor–bearing immune cells, inhibiting growth of HER2-overexpressing tumor cells.
YES
DIRECT
Binds HER2 on target cells and engages Fcγ receptor–bearing immune cells (e.g., NK cells) to mediate antibody‑dependent cellular cytotoxicity, leading to lysis of HER2+ cells.
Autologous chimeric antigen receptor T-cell therapy engineered to recognize a B-lineage surface antigen and kill antigen-positive cells, depleting autoreactive B-lineage cells to reduce autoantibody production in SLE.
Autologous T cells engineered with a chimeric antigen receptor that recognizes a B-lineage surface antigen; upon antigen binding, CAR T cells become activated and cytotoxically eliminate antigen-positive B-lineage cells (e.g., autoreactive B cells/plasmablasts), thereby depleting autoantibody-producing cells and reducing pathogenic autoimmunity in SLE.
YES
DIRECT
CAR T cells bind the target B-lineage antigen and directly kill antigen-positive cells via perforin/granzyme-mediated cytolysis and death-receptor apoptosis.
Therapeutic DNA vaccine encoding HPV16 E6/E7 antigens that targets antigen-presenting cells to enhance cross-presentation and prime HPV16-specific CD8+ cytotoxic and CD4+ helper T-cell responses.
Plasmid DNA therapeutic vaccine encoding HPV16 E6/E7 fused to an APC‑targeting unit. Following intramuscular delivery, the plasmid drives expression of E6/E7 and an APC‑binding protein, promoting APC uptake, maturation, and cross-presentation on MHC I/II, thereby priming HPV16‑specific CD8+ cytotoxic and CD4+ helper T‑cell responses to lyse HPV16 E6/E7–expressing tumor cells.
YES
INDIRECT
APC-targeted DNA vaccine primes HPV16 E6-specific CD8+ T cells via cross-presentation; CTLs recognize E6 peptides on MHC I and kill target cells by perforin/granzyme-mediated lysis.
CD20×CD3 bispecific antibody that redirects T cells to kill CD20-positive B cells; administered subcutaneously.
Humanized CD20×CD3 bispecific antibody that binds CD20 on malignant B cells and CD3 on T cells, cross-linking them to redirect and activate T cells, inducing cytotoxic killing of CD20-positive B cells; administered subcutaneously.
YES
DIRECT
CD20×CD3 bispecific antibody crosslinks T cells to CD20+ cells, activating T-cell cytotoxicity (perforin/granzyme) to lyse CD20-expressing B cells.
Therapeutic DNA vaccine encoding HPV16 E6/E7 antigens that targets antigen-presenting cells to enhance cross-presentation and prime HPV16-specific CD8+ cytotoxic and CD4+ helper T-cell responses.
Plasmid DNA therapeutic vaccine encoding HPV16 E6/E7 fused to an APC‑targeting unit. Following intramuscular delivery, the plasmid drives expression of E6/E7 and an APC‑binding protein, promoting APC uptake, maturation, and cross-presentation on MHC I/II, thereby priming HPV16‑specific CD8+ cytotoxic and CD4+ helper T‑cell responses to lyse HPV16 E6/E7–expressing tumor cells.
YES
INDIRECT
APC-targeted DNA vaccine primes HPV16 E7–specific CD8+ T cells; CTLs recognize E7 peptide–MHC I on tumor cells and kill them via perforin/granzyme-mediated apoptosis (with CD4 help).